CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 34 enrolled
Drug / intervention
Gene Expression Analysis +4 moregenetic
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02551718
NCT02551718N/ACompleted
CompareCT.gov

Individualized Treatment for Relapsed/Refractory Acute Leukemia Based on Chemosensitivity and Genomics/Gene Expression Data

University of Washington·interventional·Posted Sep 16, 2015·Updated Jun 30, 2022

In Brief

A clinical study evaluating Chemosensitivity Assay, Cytology Specimen Collection Procedure, and 3 other interventions for Recurrent Acute Leukemia of Ambiguous Lineage and 5 related conditions. Completed, enrolled 34 participants across 1 site.

Detailed Summary

This pilot clinical trial studies the feasibility of choosing treatment based on a high throughput ex vivo drug sensitivity assay in combination with mutation analysis for patients with acute leukemia that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory). A high throughput screening assay tests many different drugs individually or in combination that kill leukemia cells in tiny chambers at the same time. High throughput drug sensitivity assay and mutation analysis may help guide the choice most effective for an individual's acute leukemia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Acute Leukemia of Ambiguous Lineage
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 16, 2015
Enrollment StartSep 11, 2015
Primary CompletionJun 19, 2020
Study CompletionMay 13, 2021
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 10.8 years ago

Interventions

Chemosensitivity Assayother

Lab test in which leukemia cells obtained from blood or bone marrow are tested for sensitivity to 115 drugs individually and in certain combinations

Cytology Specimen Collection Procedureother

Undergo blood or bone marrow collection

Gene Expression Analysisgenetic

Analysis of leukemia cell genes to identify possible drug targets

Genetic Variation Analysisgenetic

Analysis of leukemia cell genes to identify possible drug targets

In Vitro Sensitivity-Directed Chemotherapydrug

Receive personalized chemotherapy with one or more of the following drugs: Afatinib Arsenic trioxide Axitinib Azacitidine Bexarotene Bortezomib Bosutinib Busulfan Cabazitaxel Cabozantinib Carfilzomib Ceritinib Cladribine Clofarabine Crizotinib Cytarabine HCl Dabrafenib Dasatinib Daunorubicin HCl Decitabine Erlotinib Etoposide Everolimus Fludarabine Gefitinib Gemcitabine HCl Hydroxyurea Imatinib Irinotecan Lapatinib Lomustine Melphalan Mercaptopurine Methotrexate Mitoxantrone Nelarabine Nilotinib Paclitaxel Pazopanib Pentostatin Ponatinib Pralatrexate Rapamycin Regorafenib Romidepsin Ruxolitinib Sorafenib Sunitinib Temsirolimus Thioguanine Topotecan HCl Trametinib Tretinoin